Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
Progress Report: How Our Top Stock Picks of 2026 Are Faring
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment
Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.
CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.
VO: Mid Caps Now Look Attractive, But Vanguard's $103 Billion ETF Misses The Mark
VO is a low-cost ETF offered by Vanguard, providing broad exposure to U.S. mid-cap stocks as defined by CRSP. However, CRSP Indexes allow overlap with the small/large-cap segments, impacting efficiency. As is common for Vanguard ETFs, VO will most likely deliver average category returns year to year, as it has done historically. However, it's not ideal from a fundamentals perspective. This article suggests combining XMHQ and XMMO to create a high-quality portfolio with strong momentum characteristics, potentially allowing for lesser drawdowns and faster recoveries.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
